Shares of biotech company Celsion soared 10% in intraday trading after the company announced an agreement with Chinese drugmaker Zhejiang Hisun Pharmaceutical. With phase 3 clinical trial results for the company's flagship drug, ThermoDox, due to be released before the end of the month, this announcement has added a new dimension to this stock's story. In this video, our health care analysts Max Macaluso and Brenton Flynn break down the details of this agreement and discuss what investors must watch in the coming days.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article New Hope for Celsion Investors? originally appeared on Fool.com.Brenton Flynn has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.